Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting the eicosanoid pathway in non-small-cell lung cancer Horn L; Backlund M; Johnson DHExpert Opin Ther Targets 2009[Jun]; 13 (6): 675-88Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with upregulation of COX-2 synthesize high levels of prostaglandin E(2) (PGE(2)), which in turn are associated with increased production of proangiogenic factors and enhanced metastatic potential. These findings indicate that an increase in COX-2 expression may play a significant role in the development and growth of lung cancers and possibly with the acquisition of an invasive and metastatic phenotype. Consequently, inhibitors of COX-2 are being studied for their chemopreventative and therapeutic effects in individuals at high risk for lung cancer and patients with established cancers.|Antineoplastic Agents/*therapeutic use[MESH]|Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism[MESH]|Cyclooxygenase 2 Inhibitors/*therapeutic use[MESH]|Cyclooxygenase 2/genetics/*metabolism[MESH]|Eicosanoids/*metabolism[MESH]|Gene Expression Regulation, Enzymologic[MESH]|Gene Expression Regulation, Neoplastic[MESH]|Humans[MESH]|Lung Neoplasms/drug therapy/*metabolism[MESH]|Up-Regulation[MESH] |